Keystone Symposia | Scientific Conferences on Biomedical and Life Science Topics

The Potent New Anti-Tumor Immunotherapies (D1)

Organizer(s): Nicholas P. Restifo
March 28 - April 2, 2007
Fairmont Banff Springs · Banff, Alberta
Abstract Deadline: November 28, 2006
Late Abstract Deadline: January 12, 2007
Scholarship Deadline: November 28, 2006
Early Registration Deadline: January 29, 2007

Sponsored by sanofi-aventis

The University of Colorado School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Colorado School of Medicine designates this educational activity for a maximum of 28-35 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

To receive CME credits, mark the box on the registration form, and pay the additional $50.00.

This meeting took place in the 2007 season.

For a complete list of the meetings for the upcoming/current season,
see our meeting list, or search for a meeting.

Summary of Meeting
For the first time, significant numbers of patients with some solid cancer histologies can be successfully treated using immunological means. Progress in our understanding of immune activation, homeostasis and regulation has reached a “tipping point” that has enabled the development of multiple anti-tumor immune-based strategies. Adoptive cell transfer (ACT) of anti-tumor T cells after the depletion host immune cells causes objective regression in about 50% of the patients. Work on therapeutic cancer vaccines is intensive and will actively be discussed at the meeting. The challenge now is to control and direct the potent new weapons in at the immunotherapist’s disposal. This meeting will bring the key scientists who are securing the basic foundations of the new immunology and the translational immunotherapists who are pioneering strategies that objectively work in the clinic.

Objectives
Upon completion of this conference, participants should be able to:

To examine evidence indicating a role for CD8+ T cells as the ultimate effectors of the adaptive anti-tumor immune response.
To critically assess the identities of the target antigens recognized by tumor-reactive CD8+ T cells, which have been revealed to be largely non-mutated “self” antigens that are also expressed by tumor cells (self/tumor antigens).
To consider the manifold functional roles of subsets of tumor antigen-specific CD4+ T cells, which may play the dual role of helping and hindering anti-tumor immune responses.

Wednesday, March 28
3:00 - 7:30 PM	Registration	Van Horne Foyer
6:30 - 7:30 PM	Refreshments	Van Horne Foyer
7:30 - 9:30 PM	Keynote Address	Van Horne AB

	David Baltimore, California Institute of Technology Engineering Immunity to Cancer and other Diseases

	Luigi M. Naldini, San Raffaele Telethon Institute Novel Approaches to Regulate Transgene Expression and Enhance the Efficacy and Safety of Gene Therapy

Thursday, March 29
7:00 - 8:00 AM	Breakfast	Alberta, New Brunswick, Cascade, Conservatory
8:00 - 9:00 AM	Morning Lecture	Van Horne AB
	Steven A. Rosenberg, National Institutes of Health Current Immunotherapies Based on Lymphodepletion and Adoptive Cell Transfer
9:00 - 9:20 AM	Coffee Break	Van Horne Foyer
9:20 - 11:15 AM	Adoptive Immunotherapy	Van Horne AB
	Malcolm K. Brenner, Baylor College of Medicine Adoptive Immunotherapy of EBV-Associated Malignancies with EBV-Specific Cytotoxic T-Cell Lines
	Philip D. Greenberg, University of Washington Engineering T Cells for Adoptive Transfer
	* James P. Allison, Memorial Sloan-Kettering Cancer Center Immune Checkpoint Blockade in Cancer Therapy
11:15 AM - 1:00 PM	Poster Setup	Alberta, New Brunswick, Cascade, Conservatory
1:00 - 10:00 PM	Poster Viewing	Alberta, New Brunswick, Cascade, Conservatory
2:00 - 3:30 PM	Editor's Forum	Van Horne AB
	* Linda J. Miller, Nature & the Nature Journals Scientific Journals, Plagiarism and Fraud



	Juan Carlos Lopez, Nature Medicine Challenges in Producing (and Publishing) Translational Research

	Heather L. Van Epps, Rockefeller University Press 1896: Experimental Medicine Then and Now


3:30 - 4:30 PM	Special Lecture	Van Horne AB
	Dario A.A. Vignali, St. Jude Children's Research Hospital Regulatory T Cell Function is Mediated by the Novel Inhibitory Cytokine Interleukin-34

4:30 - 5:00 PM	Coffee Available	Van Horne Foyer
5:00 - 7:00 PM	Programing of T Cells and Differentiation	Van Horne AB
	Carl H. June, University of Pennsylvania Adoptive Immunotherapy: New Ways to Skin the Cat?
	Federica Sallusto, Institute for Research in Biomedicine Understanding the Generation and Function of Memory T Cell Subsets
	* Stephen P. Schoenberger, La Jolla Institute for Allergy and Immunology Programmed Tolerance of CD8+ T Cells by B Cell APC

7:00 - 8:00 PM	Social Hour w/ Lite Bites	Alberta, New Brunswick, Cascade, Conservatory
7:30 - 10:00 PM	Poster Session 1	Alberta, New Brunswick, Cascade, Conservatory
Friday, March 30
7:00 - 8:00 AM	Breakfast	Alberta, New Brunswick, Cascade, Conservatory
8:00 - 9:00 AM	Morning Lecture	Van Horne AB
	Nicholas P. Restifo, National Cancer Institute, National Institutes of Health The Future of Adoptive Immunotherapy
9:00 - 9:20 AM	Coffee Break	Van Horne Foyer
9:20 - 11:30 AM	Lymphodepletion	Van Horne AB
	* Charles D. Surh, The Scripps Research Institute Potentials of T Cell Homeostatic Cytokines
	Yang Liu, University of Michigan, Ann Arbor Short Talk: CD24 Controls T Cell Homeostasis and Cancer Resistance
	Hyam I. Levitsky, Johns Hopkins School of Medicine In vivo Depletion of Immune Regulatory Factors
	Stanley R. Riddell, Fred Hutchinson Cancer Research Center Establishing T Cell Memory by Adoptive Transfer of T Cell Clones
11:30 AM - 1:00 PM	Poster Setup	Alberta, New Brunswick, Cascade, Conservatory
1:00 - 10:00 PM	Poster Viewing	Alberta, New Brunswick, Cascade, Conservatory
2:00 - 2:30 PM	Special Lecture	Van Horne A/B
	Robert H. Wiltrout, National Cancer Institute, National Institutes of Health, Center for Cancer Research Immunotherapy of Cancer by IL12-based Cytokine Combinations
2:30 - 4:30 PM	Workshop 2A	Van Horne A/B



	Phillip K. Darcy, Peter MacCallum Cancer Centre Investigation of the Role of Gene-Modified CD4+ T Cell Subsets for Cancer Immunotherapy


	Wolfgang Uckert, Humboldt-University Enhanced Functional Expression of T Cell Receptors by Genetic Modification and Vector Optimization

	Jacob Schachter, Sheba Medical Center Adoptive Immunotherapy
	Antoni Ribas, University of California, Los Angeles PET Imaging of Adoptive Transfer Immunotherapy
	* Michael H. Kershaw, Peter MacCallum Cancer Center Targeting a Carbohydrate Antigen using T Cells Modified with a Humanized Chimeric Receptor Gene
2:30 - 4:30 PM	Workshop 2B	Van Horne C
	Mary Jo Turk, Dartmouth Hitchcock Medical Center The Induction of T Cell Memory in the Absence of Tregs after Surgical Excision
	Shimon Slavin, Hadassah University Hospital Cell-Mediated Immunotherapy of Hematological Malignancies and Metastatic Solid Tumors
	Weiping Zou, University of Michigan Tregs, Th17 and their regulation in the tumor microenvironment

	Sjoerd H. van der Burg, Leiden University Medical Center Human Tumor-Specific Regulatory T-Cells in Therapeutic Vaccination Strategies
	Jill E. Slansky, University of Colorado Health Sciences Center Relating TCR-Peptide-MHC Affinity to Immunogenicity
	* Karin U. Jooss, Cell Genesys Inc. GM-CSF Transduced Cancer Cell Immunotherapies in Combination with Anti-CTLA4: Of Mice and Men
4:30 - 5:00 PM	Coffee Available	Van Horne Foyer
5:00 - 7:00 PM	Triggering Self Recognition	Van Horne AB
	Pamela S. Ohashi, Ontario Cancer Institute Cytokines are critical regulators of anti-tumor immunity
	Suzanne L. Topalian, Johns Hopkins University School of Medicine Short Talk: The Hybrid Nature of Altered Self: Structural Basis for MHC Class II-Restricted TCR Recognition of a Mutant Tumor Antigen
	Elizabeth M. Jaffee, Johns Hopkins University Tipping the Immune System Balance in Favor of Effective Anti-Cancer Therapy
	* Linda A. Sherman, The Scripps Research Institute Immune Tolerance to Persistent Antigens and Dealing with the Consequences for Tumor Immunotherapy
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Alberta, New Brunswick, Cascade, Conservatory
7:30 - 10:00 PM	Poster Session 2	Alberta, New Brunswick, Cascade, Conservatory
Saturday, March 31
7:00 - 8:00 AM	Breakfast	Alberta, New Brunswick, Cascade, Conservatory
8:00 - 11:00 AM	Dendritic Cells	Van Horne AB

	* Anna Karolina Palucka, Baylor Institute for Immunology Research Understanding the Interplay of the Human Immune System with Cancer in Humanized Mice
	Lieping Chen, Johns Hopkins School of Medicine Co-Stimulatory and Co-Inhibitory Receptor-Ligand Pairs
	Vincenzo Cerundolo, University of Oxford Harnessing NKT cells in cancer vaccination strategies
	Andrew L. Mellor, Medical College of Georgia Immunoregulatory Plasmacytoid Dendritic Cells Expressing Indoleamine 2,3 Dioxygenase (IDO)
	Patrick Hwu, University of Texas MD Anderson Cancer Center Short Talk: Use of Activated Plasmacytoid Dendritic Cells to Induce Antitumor Immunity
9:20 - 9:40 AM	Coffee Break	Van Horne Foyer
11:00 AM - 1:00 PM	Poster Setup	Alberta, New Brunswick, Cascade, Conservatory
1:00 - 10:00 PM	Poster Viewing	Alberta, New Brunswick, Cascade, Conservatory
2:00 - 2:30 PM	Special Lecture	Van Horne AB
	Vincenzo Bronte, Istituto Oncologico Veneto Myeloid Suppressor Cells in Cancer
2:30 - 4:30 PM	Workshop 3A	Van Horne A/B

	Franck Housseau, Johns Hopkins School of Medicine Interferon-Producing Killer Dendritic Cells

	Naoto Hirano, Dana Farber Cancer Institute IL-21 Mediated Expansion of Antigen-Speciific CD8+ T Cells
	Diana F. Hausman, ZymoGenetics Inc. Clinical Studies of IL-21 in the Immunotherapy of Cancer
	Reno Debets, Erasmus MC-Daniel IL-21 Promotes Naieve T Cell Phenotype and Antigen-Specific Functions in TCR-Transduced T Cells

	* Gosse J. Adema, University Medical Center, NCMLS Nijmegen The Impact of Toll-Like Receptors on Regulatory T Cells
2:30 - 4:30 PM	Workshop 3B	Van Horne C

	Peter P. Lee, Stanford University School of Medicine Downregulation of Interferon-Signaling Pathways in Lymphocytes from Metastatic Melanoma Patients

	Paul R. Walker, Geneva University Hospital Functional Differentiation of CD8 T Cells during the Effector Phase of Brain Tumor Immunity

	Nathalie Rufer, Swiss Institute for Experimental Cancer Research In vivo Clonal Distribution and Longevity of Functional Human Tumor Antigen Specific T Cells
	* George Coukos, University of Pennsylvania Regulation of T Cell Trafficking by Tumor Endothelium: Implications for Immunotherapy
	Mikael J. Pittet, Center for Molecular Imaging Research Noninvasive in vivo Assessment of CTL Delivery at the Tumor Site
	Michelle Krogsgaard, New York University Imaging Sensitivity of T-Cell Recognition of Melanoma Antigens
4:30 - 5:00 PM	Coffee Available	Van Horne Foyer
5:00 - 7:00 PM	Visualizing T Cell Target Cell Interactions in Real-Time	Van Horne AB
	* Mark M. Davis, Stanford University T Cell Recognition
	Andrey S. Shaw, Washington University School of Medicine Antigen Recognition and Immunological Synapse Formation
	Alex Y.C. Huang, Case Western Reserve University School of Medicine Short Talk: Chemokine Guidance of Cellular Cooperation During Primary Adaptive Immune Response
	Rajat Varma, LCMI, NIAID, National Institutes of Health Short Talk: A Dynamic View of the Immunological Synapse

7:00 - 8:00 PM	Social Hour w/ Lite Bites	Alberta, New Brunswick, Cascade, Conservatory
7:30 - 10:00 PM	Poster Session 3	Alberta, New Brunswick, Cascade, Conservatory
Sunday, April 1
7:00 - 8:00 AM	Breakfast	Alberta, New Brunswick, Cascade, Conservatory
8:00 - 9:00 AM	Concluding Keynote Address	Van Horne AB
	Rafi Ahmed, Emory University School of Medicine Inducing Functional Immune Responses or CD8 T Cell Memory
9:00 - 9:20 AM	Coffee Break	Van Horne Foyer
9:20 - 11:30 AM	Genetically Engineering Cells for Adoptive Immunotherapy	Van Horne AB

	Ton N. Schumacher, Netherlands Cancer Institute Prospects and Limitations of T Cell Receptor Gene Therapy
	Ken-ichi Hanada, National Cancer Institute, National Institutes of Health Short Talk: Genetic Engineering of T Cells for the Recognition of Renal Cell Tumors
	Juan Carlos Zúñiga-Pflücker, Sunnybrook Research Institute From Stem Cells to T-Cells in vitro, a Toolkit for Cellular Immunotherapy
	Drew M. Pardoll, Johns Hopkins University School of Medicine Cancer Immunotherapy via Manipulation of T Cell Activation and Tumor Microenvironment
2:00 - 4:30 PM	Workshop 4A	Van Horne A/B

	* Lili Yang, California Institute of Technology Gene Modification of Hematopoietic Stem Cells
	Linda Liu, Maxcyte Corp Genetically Engineering Cells at Industrial Scale for Immunotherapy
	Hans J. Stauss, Royal Free College Exploiting T Cell Receptor Genes for Cancer Immunotherapy
	Michel Sadelain, Memorial Sloan-Kettering Cancer Center Novel Genetic Strategies to Enhance T Cell Function

	Cyrille J. Cohen, Bar-Ilan University Genetically Engineering Human T Cell Receptor Structure
2:00 - 4:30 PM	Workshop 4B	Van Horne C



	* Thomas F. Gajewski, University of Chicago T Cell Anergy as a Mechanism of Immune Escape
	Charles Drake, Johns Hopkins University STAT3 is required for Il-17 and Il-23 in the Tumor Microenvironment
	Pawel Kalinski, University of Pittsburgh Reciprocal Impact of Effector and Memory CD8+ T Cells on the Effectiveness of Cancer Vaccines
	Mark Selby, Medarex, Inc. Combination of CTLA-4 and PD-1 Blockade Induces Potent Anti-Tumor Responses
	Martin L. Ashdown, ImmunAid P/L Breaking a Deadly Cycle: Succesful Timed Treg Lymphodepletion in Cancer - Is it Already Happening Accidentally in the Oncology Clinic with Standard Drugs?
	Wilfred A. Jefferies, University of British Columbia Epigenetic Control of the Immune Escape Mechanisms in Malignant Carcinomas

	Annette Paschen, German Cancer Research Center Generation of the Melan-A/MART-1 CTL Epitope - How Cellular Proteases Reduce the Specific T Cell Stimulatory Capacity of Melanoma
4:30 - 5:00 PM	Coffee Available	Van Horne Foyer
5:00 - 7:00 PM	Future Work for the Clinic	Van Horne AB
	Rienk Offringa, Leiden University Medical Center The Potential and Pitfalls of Targeting Cancer through Self-Antigens
	Pedro Romero, Ludwig Institute for Cancer Research New Clinical Vaccine Trials

	* Bruce R. Blazar, University of Minnesota Umbilical Cord Blood Transplant (UCBT) as a Platform for Inducing Anti-Leukemia Immune Responses
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Alberta, New Brunswick, Cascade, Conservatory
8:00 - 11:00 PM	Entertainment	Alberta, New Brunswick, Casade, Conservatory
Monday, April 2
	Departure

*Session Chair †Speaker invited, not yet responded.